メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
岡山大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
設備
活動
プレス/メディア
受賞
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
渡邉 豊彦
教授
,
医学部
教授
,
ヘルスシステム統合科学学域
h-index
1468
被引用数
22
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
1993 …
2022
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(205)
類似のプロファイル
(6)
フィンガープリント
Toyohiko Watanabeが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Clear Cell Renal Cell Carcinoma
51%
Prostate Cancer
49%
Urodynamics
48%
Computer Assisted Tomography
44%
Biopsy
44%
Prostatectomy
42%
Kidney Function
41%
Bladder Outlet Obstruction
33%
Diagnosis
32%
Transitional Cell Carcinoma
32%
Cryoablation
30%
Partial Nephrectomy
30%
Germinoma
30%
Robot-Assisted Prostatectomy
28%
Overall Survival
25%
Bleomycin
24%
Quality of Life
23%
Ureteroscopy
22%
Doppler Flowmetry
22%
Cystectomy
22%
Neoplasm
22%
Upper Urinary Tract
22%
Clinical Study
21%
Recurrent Disease
21%
Urine Incontinence
20%
Pulmonary Toxicity
20%
Pelvic Organ Prolapse
20%
Laparoscopic Surgery
20%
Gleason Score
20%
Spinal Cord Injury
20%
Nivolumab
20%
Ipilimumab
20%
Doppler Ultrasonography
19%
Metastatic Carcinoma
18%
Nephrectomy
18%
Cisplatin
18%
Symptom
17%
Malignant Neoplasm
17%
Combination Therapy
16%
Operation Duration
15%
Urinary System
15%
Progression Free Survival
15%
Levofloxacin
15%
Diabetes Mellitus
15%
Bleeding
15%
Scoring System
15%
Lymphocyte
15%
Skeletal Muscle
15%
Stress Incontinence
15%
Kidney Transplantation
15%
Pharmacology, Toxicology and Pharmaceutical Science
Urinary Tract Infection
100%
Clinical Study
72%
Antibacterial Activity
39%
Infection
35%
Prostate Hypertrophy
30%
Escherichia coli
24%
Ofloxacin
24%
Side Effect
21%
Lower Urinary Tract Symptom
20%
Ritipenem Acoxil
20%
Spinal Cord Injury
20%
Germ Cell Tumor
20%
Naftopidil
20%
Clinical Pharmacokinetics
20%
Intravaginal Administration
20%
Azithromycin
20%
Cystitis
19%
Quinolone Derivative
18%
Antiinfective Agent
18%
Levofloxacin
18%
Overall Survival
15%
Symptom
14%
Clinical Trial
14%
Cisplatin
13%
Ritipenem
12%
Ceftazidime
12%
Pharmacokinetics
12%
Retrospective Study
12%
Bleomycin
12%
Vancomycin
12%
Progression Free Survival
11%
Incontinence
11%
Imipenem
10%
Tacrolimus
10%
Rituximab
10%
Case-Control Study
10%
Pembrolizumab
10%
Resiniferatoxin
10%
Loracarbef
10%
Antimicrobial Therapy
10%
Goshajinkigan
10%
Tadalafil
10%
Cefoselis
10%
Balofloxacin
10%
Vonoprazan
10%
Normal Human
10%
Rabeprazole
10%
Holmium
10%
Hyperreflexia
10%
Transitional Cell Carcinoma
10%
Keyphrases
Antibacterial Activity
59%
Clinical Efficacy
58%
Urinary Tract Infection
40%
Recurrent Urinary Tract Infections (rUTIs)
40%
Efficacy Rate
23%
Imipenem
22%
Chronic Pelvic Pain Syndrome
20%
Chronic Prostatitis
20%
Prostatic Fluid
20%
Educational Program
20%
Laparoscopic Surgery
20%
Renal Cell Carcinoma
20%
Antibiotics
18%
Genitourinary Infection
17%
Uncomplicated UTI
16%
Cefoperazone
16%
Acute Cystitis
15%
Ceftazidime
15%
Ipilimumab
13%
New Quinolone
13%
Cefixime
12%
Ofloxacin
12%
Clinical Side Effects
10%
Non-preemptive
10%
Preemptive Kidney Transplantation
10%
Symptom Response
10%
Mental Satisfaction
10%
Resiniferatoxin
10%
Loracarbef
10%
Heterosexual Men
10%
Goshajinkigan
10%
Chlamydia Trachomatis
10%
BK Virus Nephropathy
10%
Stress Incontinence
10%
Extracorporeal Magnetic Innervation
10%
Randomized Double-blind
10%
Orchiectomy
10%
Renal Ischemia Reperfusion
10%
Tadalafil
10%
Neutrophil Dynamics
10%
Vonoprazan
10%
Laparoscopic Management
10%
Ureteral Calculi
10%
Ureteroureterostomy
10%
Urinary Tract Reconstruction
10%
Urachal Remnant
10%
Renal Parenchymal Volume
10%
Pathological Upgrading
10%
Gleason Grade Group
10%
Bladder Outlet Obstruction
10%